Abstract
Recent evidence suggests that buprenorphine, the partial opiate receptor agonist, exhibits equal efficacy as methadone in reducing withdrawal and craving for opiates in opioid dependence. Very few studies examine the benefits of screening for combined cardiovascular and metabolic risk factors in methadone and buprenorphine maintenance options for opioid dependence. We explore the feasibility whether outcome maybe improved through developing cardio-metabolic screening strategy in treatment facilities for opioid addiction.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
